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SUMMARY: Müllerian adenosarcoma with sarcomatous overgrowth presented by a 52-year-old female patient after adjuvant tamoxifen treatment
for breast carcinoma is described. The diagnosis was made on histological basis after curettage and complementary total hysterectomy with bilateral
salpingo-oophorectomy. The immunohistochemical study showed high expression of estrogen receptors in the epithelial component of the lesion and
irregularly positive findings in the stroma. The proliferative activity evaluated by Ki-67 immunoexpression was higher in the stroma than the epithelium.
Some of the stromal cells showed rhabdomyoblastic differentiation. The association of tamoxifen use and development of mesenchymal neoplasms is
discussed.
DESCRIPTORS: Uterine adenosarcoma. Breast cancer. Tamoxifen. Uterine sarcoma.
Adenosarcomas are characterized
as tumors containing benign or atypi-
cal epithelial and malignant stromal
components. They present as polypoid
masses arising from the endometrium
and can invade the subjacent myo-
metrium. Most adenosarcomas are tu-
mors of low malignant potential. Re-
currence occurs in approximately 24%
of cases and is related to deep myome-
trial invasion5. A variant from the usual
pattern with a sarcomatous overgrowth
has been described by Clement6. This
variant is an overgrowth of the ade-
nosarcoma by a pure sarcoma with
consequent higher recurrence rate, me-
tastases, and fatal outcome6.
Of the 100 cases described by
Clement and Scully, 5 had a history of
estrogen use; 1 had a history of mater-
nal usage of a hormone of unknown
type during the first trimester of preg-
nancy, and 1had a diagnosis of Stein-
Leventhal syndrome5. Two patients of
this series had carcinoma of the breast
that was treated 5 and 2.5 years ear-
lier5. Recently, Mourits et al. (1998)
described a case of a 71-year-old pa-
tient who developed a uterine adenosa-
rcoma after two years of adjuvant
tamoxifen treatment for breast cancer13.
We discuss the role of tamoxifen on
the benign and malignant stromal pro-
liferation of the endometrium and
present a case of adenosarcoma with
sarcomatous overgrowth in a woman
receiving antiestrogen therapy for
breast cancer with tamoxifen.
CASE  REPORT
A 52–year-old multiparous woman
underwent left mastectomy and right
quadrantectomy for bilateral breast
cancer, clinical stage II. Both tumors
were invasive ductal carcinoma. The
pathological stages were pT2, pN2 and
pT2, pN1biii, respectively at left and
right. The surgical treatment was fol-
lowed by 6 cycles of taxol and
adriamycin and regional radiotherapy
at both breasts. Five months after the
surgery she began tamoxifen therapy
with 20 mg daily. After 6 months of
tamoxifen therapy, endometrial thick-
ness was determined by ultrasound to
be 5.8 mm. Five months later the en-
dometrial thickness was 11 mm, and 1
year later it was 27 mm. The diagno-
sis was done by curettage under gen-
eral anesthesia, and the patient under-
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went total abdominal hysterectomy
with bilateral salpingo-ooforectomy.
PATHOLOGICAL STUDY
The uterus was enlarged, weighed
230 g and measured 9.5 X 6.1 X 5.2
cm. The uterine cavity measured 8.5
cm in length and had an endometrial
polypoid lesion measuring 4.0 cm that
was partially necrotic with signs of su-
perficial myometrial invasion. (Fig. 1).
The microscopic examination showed
a biphasic neoplasm with glands of
endometrioid pattern and a cellular
stromal component that tended to coa-
lesce into more densely hypercellular
cuffs around the epithelial component
(Fig. 2). The stromal cells were
spindle-shaped or pleomorphic and had
rhabdoid areas (Fig. 3). The mitotic
count was 6 per 10  high power field
(HPF). Areas of prominent stromal
component accounted for 40% of the
tumor. There were foci of stromal fi-
brosis and hemorrhage without necro-
sis. Vascular invasion was not seen.
There were areas of superficial myo-
metrial invasion.
The immunohistochemical study
was carried out to identify estrogen re-
ceptor (ER), proliferative activity, and
rhabdomyoblastic differentiation with
the monoclonal antibodies 1D5
(Dako), MIB-1 (Immunotech) and
desmin DE-R-11 (Dako), respectively.
Eighty percent of epithelial cells were
positive for estrogen receptors, and
stromal cells were irregularly positive
for estrogen receptors. Twenty percent
of stromal cells and 5% of epithelial
cells were positive for MIB1, indica-
ting that the proliferative activity was
higher in the stroma. The more pleo-
morphic areas were positive for
Figure 1 - Product of total hysterectomy with
polypoid lesion in the endometrium.
Figure 2 - Histological aspect of the endometrial lesion, showing the epithelial and stromal component.
Note the hypercellular area near the gland (hematoxylin-eosin; 100X).
Figure 3 - Area of neoplastic stroma with pleomorphic and rhabdoid cells (hematoxylin-eosin; 400X).
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desmin, indicating muscular differen-
tiation.
DISCUSSION
Breast cancer treatment with
tamoxifen has been associated with the
development of hyperplasia and carci-
nomas of the endometrium17. However,
the most common finding has been
uterine polyps8,10,18,19. Fotiu et al.11 have
studied the histopathologic features of
50 curettage specimens from patients
under tamoxifen treatment and experi-
encing abnormal bleeding; 44% had
cervical and endometrial polyps. A
clinical study of 245 cases has found
an association of endometrial polyps
and tamoxifen in 8% of patients with
breast cancer.15 Exacoustos et al.10 have
observed thicker endometrium in pa-
tients receiving tamoxifen compared to
controls. In that study, 23 cases of
pathological endometrium out of 38
cases were observed: 19 polyps and 4
hyperplasia10.
Tesoro et al.19 found 24 cases of
abnormal endometrium in a group of
80 postmenopausal women treated
with tamoxifen for breast cancer:  13
polyps, 5 hyperplasia, 3 tubal metapla-
sia, 2 carcinomas, and 1 breast carci-
noma metastatic to endometrium.19
Polypoid structures, morphologically
similar to endometrial polyps, were
observed even in endometriotic foci in
patient under tamoxifen treatment16.
The occurrence of polyps is increased
in tamoxifen-treated postmenopausal
women compared with untreated pa-
tients, but this alteration is not ob-
served in premenopausal tamoxifen-
treated12. On the other hand, some
workers have found lower levels of es-
trogen and progesterone receptors in
endometrium of postmenopausal
tamoxifen-treated patients than in con-
trol groups composed of healthy
women with and without estrogen re-
placement therapy7. In our study, posi-
tivity for ER was lower in the stromal
component of the lesion compared
with the epithelium and inversely pro-
portional to the proliferative activity.
This finding was the same as that no-
ticed by others 13 and can be explained
by a loss of expression of steroid re-
ceptors due to neoplastic transforma-
tion. Considering that the epithelial
component is not neoplastic yet, it ex-
presses high levels of receptor. This
finding can explain the development of
hyperplastic lesions and carcinomas in
some endometria. Some groups have
found carcinoma arising within
tamoxifen-associated endometrial pol-
yps14.
There are many reports of sarcomas
in patients under tamoxifen use1,2,4,18.
Clement et al.4 described 6 cases of
uterine adenosarcomas associated with
tamoxifen therapy. Considering the rar-
ity of these tumors, it seems that the
association of tamoxifen therapy with
mesenchymal neoplasm is higher than
expected.
The proliferative effect of
tamoxifen in endometrium seems to be
related to an effect primarily on stro-
mal cells and perhaps on vascular
structures. The polyps, so frequently
associated with tamoxifen use, are pro-
liferation with an important stromal-
vascular component. Zhao et al.20 have
shown that endometria of women re-
ceiving tamoxifen express
adrenomedullin, a growth factor for
endotelial cells, postulating that induc-
tion of this angiogenic factor is part of
the mechanism by which tamoxifen re-
sults in endometrial hyperplasia.
Bhargava et al.3, using in vitro model,
have found an increase in the prolifera-
tive activity due to tamoxifen in the
endometrial stromal cells over the con-
trols. Decensi et al.9 compared en-
dometria of tamoxifen-treated breast
cancer patients and controls and have
observed an antiproliferative effect of
tamoxifen on the epithelium and a
growth-promoting effect on the stroma,
suggesting that the endometrial prolif-
eration is mediated by the stromal
component.
In conclusion, the exact mechanism
regarding the role of tamoxifen in the
development of epithelial and mesen-
chymal neoplasms remains unclear, but
there is no doubt that all cases of en-
dometrial thickening must be investi-
gated in tamoxifen users.
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É descrito o caso de uma paciente
do sexo feminino, 52 anos, com
adenossarcoma Mülleriano com
componente sarcomatoso predomi-
nante, que se apresentou após
tratamento adjuvante com tamoxifeno
para câncer de mama. O diagnóstico
foi feito em bases histológicas após
curetagem uterina e histerectomia to-
tal complementar com anexectomia bi-
lateral. O estudo imuno-histoquímico
mostrou alta expressão de receptores
de estrogênio no componente epitelial
da lesão e positividade irregular no
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estroma. A atividade proliferativa
avaliada através da imunoexpressão do
Ki-67 foi maior no estroma do que no
epitélio. Algumas células estromais
mostraram diferenciação rabdomio-
blástica. A associação entre uso de
tamoxifeno e desenvolvimento de
neoplasias mesenquimais é discutida.
DESCRITORES: Adenossarcoma
uterino.  Câncer de mama.
Tamoxifen. Sarcoma uterino.
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